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Background: Patients with cystic fibrosis (CF) may suffer from sleep disturbances and reduced
health-related quality of life (HRQoL). However, the relationships of daytime sleepiness and
sleep quality to HRQoL in CF have not yet been investigated.
Patients and methods: 55 adult CF out-patients free from a pulmonary exacerbation were
prospectively enrolled in this study. Questionnaires were used to assess disease-specific HRQoL
(German version of the revised Cystic Fibrosis Questionnaire for adults, CFQ18 þ R), daytime
sleepiness (Epworth Sleepiness Scale, ESS) and sleep quality (Pittsburgh Sleep Quality Index,
PSQI). 30 age- and sex-matched healthy volunteers served as a control group.
Results: The prevalence of daytime sleepiness was higher in the CF than in the control group
(ESS > 10; n Z 11 [20%] vs. n Z 2 [6.7%]; p < 0.01) as was reduced sleep quality (PSQI > 5;
nZ 21 [38.2%] vs. nZ 1 [3.3%]; p < 0.01). Multiple regression analysis including age, gender,
body mass index, lung function and pseudomonas status showed that higher PSQI scores signif-
icantly correlated with lower CFQ18 þ R scores for vitality, emotional functioning, social, role,
eating disturbances and digestive symptoms.
Conclusion: In clinically stable adult CF out-patients self-reported daytime sleepiness and poor
sleep quality are more common than in age and sex-matched healthy controls. In addition,
impaired sleep quality is related to reduced disease-specific HRQoL in CF.
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Health-related quality of life (HRQoL) is a growing area of
research in cystic fibrosis (CF). Reduced HRQoL in CF may
be due to severe lung disease, pain or anxiety and
depression.1e3 Furthermore, it may be related to gender-
specific perceptions of physical and mental health, i.e.
females with CF have been observed to report lower
HRQoL.4 Working ability, socioeconomic status, race and
ethnicity may also play significant roles in this context.5,6
Various sleep disturbances can occur in CF. Patients with
severe airflow limitation may show REM sleep-related
hypoventilation, hypoxemia and hypercapnia.7 Further-
more, bronchial mucus accumulation and reflux of gastric
contents may cause episodes of nocturnal cough.8 Mood
disorders such as anxiety and depression may also lead to
problems with falling asleep and/or maintaining normal
sleep. Finally, chronic pain can interfere with sleep quality
in CF.9
In line with these assumptions, prior studies have found
that CF patients may have disturbed sleep architecture,
daytime sleepiness and impaired neurocognitive
function.10e14 Patients with end-stage lung disease and
frequent infective exacerbations seem to be mainly
affected by these problems.
Against this background, poor sleep quality and exces-
sive daytime sleepiness can be hypothesized to have
a negative impact on HRQoL in CF, however, this has not yet
been investigated. In the present study, we aimed to
address this issue in a cohort of adult CF patients with the
help of standard questionnaires evaluating disease-specific
HRQoL, sleep quality and the degree of daytime sleepiness.
Patients and methods
Patient recruitment and assessment
The patients of the present study were investigated during
an ambulatory visit to the Adult CF Service of the University
of Giessen Lung Center, Germany between January and
March 2012. All of them were older than 18 years of age and
had a diagnosis of CF verified by sweat tests and/or genetic
analysis. Their anthropometric parameters were deter-
mined, i.e. age, sex and body mass index (BMI). The current
use of medications was evaluated, i.e. mucolytics (aero-
solized DNAse, hypertonic saline), antibiotics (nebulized
tobramycin, colistin or aztreonam, oral azithromycin) and
bronchodilators (b2-mimetics, parasympatholytic drugs). It
was noted whether the patients were on long-term oxygen
or bilevel positive airway pressure therapy. All patients
were investigated by pulmonary function tests and blood
gas analysis from arterialized ear lobes. Finally, sputum
specimens were obtained for microbiological analysis to
determine if the patients’ airways were chronically colo-
nized with Pseudomonas aeruginosa. If three consecutive
sputum cultures showed these bacteria, the patients were
judged to have a positive pseudomonas status.
Patients had to be in a stable clinical condition, i.e.
those suffering from an ongoing or recent (i.e. within the
last 4 weeks prior to study recruitment) pulmonary exac-
erbation were excluded. This was defined as clinicalworsening (i.e. increased dyspnea, cough or sputum
volume) accompanied by abnormal findings on chest
examination (i.e. wheezing, inspiratory crackles) and/or
a significant decrease in pulmonary function.15 Patients
who had received a lung transplant were also not allowed
to participate in the study.
During the study period, a total of 69 adult CF patients
consecutively attended the outpatient clinic. Fifty-five of
them were eligible for the study, the other 14 patients had
to be excluded (4 patients had been transplanted and 10
patients presented with a pulmonary exacerbation or had
just recovered from such an episode).
Healthy volunteers matched with the CF patients for age
and gender and recruited by newspaper advertisement
served as controls. The study protocol had been approved
by the local ethics committee and all patients and controls
had given their informed written consent.Measures of quality of life, daytime sleepiness and
sleep quality
Self-administered questionnaires were used to assess
disease-specific HRQoL, daytime sleepiness and sleep
quality. Disease-specific HRQoL was judged by the German
version of the revised Cystic Fibrosis Questionnaire for
adults (CFQ18 þ R,16). This questionnaire consists of 50
items across 12 domains. Response choices generally
include ratings of frequency and difficulty on a 4-point
scale (1 Z ‘always’ to 4 Z ‘never’; 1 Z ‘a lot of diffi-
culty’ to 4 Z ‘no difficulty’) or true/false responses
(1 Z ‘very true’ to 4 Z ‘very false’). Scores are stan-
dardized on a 0- to 100-point scale, with higher scores
representing better QoL. Cut-off values separating indi-
viduals with normal from those with abnormal scores have
not yet been established on this instrument. However, for
each domain of the CFQ18 þ R mean scores for groups of
patients considered to have varying degrees of CF disease
severity have been reported.16,17 Based on this, the scores
achieved on the various domains of the CFQ18 þ R may be
judged to be mildly, moderately or severely reduced.
The Epworth Sleepiness Scale (ESS,18) was used to assess
the level of daytime sleepiness. In this questionnaire, the
probability of falling asleep in different situations (n Z 8)
has to be rated on a 4-point scale (0Z ‘never’ to 3Z ‘high
probability’). The maximal score of the ESS is 24 and values
of >10 are considered to indicate excessive daytime
sleepiness.
Finally, subjective sleep quality was evaluated by the
Pittsburgh Sleep Quality Index (PSQI,19). The PSQI consists
of 7 domains with a total of 19 questions. In each domain
a score of 0e3 can be achieved. The scores of all domains
are summarized (range: 0e21) with higher values indicating
poorer sleep quality. Based on prior validations of the PSQI
in psychiatric populations, a value of >5 may be regarded
as evidence for poor sleep quality.
The CFQ18 þ R refers to the past 2 weeks whereas the
PSQI has a time window of 4 weeks. The questions of the
ESS relate to the “last time” without any further specifi-
cations. None of the patients or controls who were asked to
take part in the study refused to complete the question-
naires. The results of the questionnaires were analyzed by
Table 1 Patient characteristics.
Total number 55
Males (n/%) 30/54.5
Age (yrs.) 34.4  7.5
BMI (kg/m2) 21.5  2.9
FEV1 (% of pred.) 59.0  23.6
VC (% of pred.) 79.0  19.4
FEV1/VC (% of pred.) 74.7  15.4
Rtot (% of pred.) 172.9  96.4
MEF 25 (% of pred.) 22.1  18.9
pO2 (mm Hg) 71.5  10.0
PCO2 (mm Hg) 38.1  4.0
Pseudomonas positive (n/%) 43/78.2
Pancreatic insufficiency (n/%) 49/89.1
Diabetes mellitus (n/%) 18/32.7
Bronchodilators (n/%) 53/96.4
Aerosolized DNAse (n/%) 35/63.6
Inhaled hypertonic saline (n/%) 29/52.7
Nebulized antibiotics (n/%) 43/78.2
Oral azithromycin (n/%) 28/50.9
Long term O2 therapy (n/%) 5/9.1
BiPAP therapy (n/%) 1/1.8
Abbreviations: BMI Z body mass index, FEV1 Z forced expira-
tory volume in 1 s, VC Z vital capacity, pO2Z partial pressure
of oxygen, PCO2 Z partial pressure of carbon dioxide,
Rtot Z total airway resistance, MEF 25 Z maximal expiratory
flow at 25% of forced VC.
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Data analysis
Data are presented as n/%, mean  standard deviation or
median  interquartile range. First, the differences of the
ESS and PSQI in the CF vs. the control group were evaluated
and the anthropometric parameters of both groups were
compared with t-test or ManneWhitney-test, as appro-
priate. With the same tests the mean scores of the
different domains of the CFQ18 þ R were compared in
sleepy vs. non-sleepy patients (ESS > 10 vs.  10) and those
with poor vs. good sleep quality (PSQI > 5 vs.  5).
Then, bivariate correlations between the scores on the ESS
and PSQI and those of the different domains of the CFQ18þ R
were calculated (Pearson’s correlation or Spearman’s rho,
respectively, p-values of these analyses are named “unad-
justed”). If data were found to be skewed, they were Ln-
transformed before further analysis. Afterward, linear
regression was performed with the determinant and outcome
variable uni-variately. In a second step, possible confounders
(i.e. age, gender, BMI, FEV1/VC and pseudomonas status)
were added to the model (method: enter). Results of multi-
variate regression analysis are named “adjusted”. SPSS 19.0
was used for calculating statistics. A p-value of <0.05 was
regarded as statistically significant.
Results
Characteristics of patients and controls
The patient characteristics are summarized in Table 1. The
mean age of the 55 patients enrolled was in the mid-thirties
with almost equal portions of males and females. On an
average, the patients had relatively well-preserved nutri-
tional status (i.e. a BMI >20 kg/m2) and moderately
reduced pulmonary function. The majority of them were
chronically infected with P. aeruginosa and regularly
inhaled bronchodilators and antibiotics. About half of the
patients inhaled mucolytics and received oral azithromycin
prophylaxis. Only a few of them were on long-term oxygen
therapy or regularly used a bilevel positive airway pressure
device.
The healthy control group consisted of 30 subjects. They
were closely matched with the CF patients with regard to
age and gender (age: 36.2  8.0 yrs, nZ 16 males [53.3%])
but had a higher BMI (24.9  3.0 kg/m2, p < 0.05 in
comparison to the CF group).
Daytime sleepiness/poor sleep quality in CF vs.
controls
On an average, the scores on the ESS and PSQI were signifi-
cantly higher in the CF than the control group (ESS: 7.5 3.9
vs. 6.0  2.7, p < 0.05; PSQI: 5.1  3.3 vs. 2.8  1.4,
p< 0.01). 11 CF patients [20%] were considered to be sleepy
(ESS > 10) and 21 [38.2%] to have reduced sleep quality
(PSQI > 5). In contrast, daytime sleepiness and poor sleep
quality were less frequently observed in the control group(nZ 2 [6.7%] with ESS > 10 and nZ 1 [3.3%] with PSQI > 5,
p < 0.01 for each comparison with the CF group).
Health-related quality of life in CF
Fig. 1 shows the results of the CFQ18 þ R in the patients
studied. When looking at the patient cohort as a whole, the
domains of the CFQ18 þ R showed moderate score reduc-
tions as related to previous validations of this instru-
ment.16,17 On almost all domains, patients who felt sleepy
or had poor sleep quality had lower scores. In sleepy vs.
non-sleepy patients, statistically significant differences
were observed for the vitality (p < 0.01), emotional func-
tioning, role and eating disturbances domains of the
CFQ18 þ R (p < 0.05, respectively). For patients with poor
vs. good sleep quality this was the case for the emotional
functioning and social domains of the CFQ18 þ R (p < 0.01
and <0.05, respectively).
Relation of daytime sleepiness/poor sleep quality
to health-related quality of life in CF
In general, daytime sleepiness as determined by the ESS
was not linked to HRQoL in the patients investigated. After
adjustment for age, gender, BMI, lung function and pseu-
domonas status, the only correlation which remained
significant between the ESS and the CFQ18 þ R scores was
that of the vitality domain (r Z 0.43, p < 0.01).
In contrast, poor sleep quality was more closely related
to reduced HRQoL in CF. On multivariate regression anal-
ysis, statistically significant inverse correlations between
Figure 1 Mean scores of the domains of the CFQ18 þ R in all CF patients (n Z 55) as well as in those with vs. without daytime
sleepiness (ESS > 10, n Z 11 vs.  10, n Z 44) and poor sleep quality (PSQI > 5, n Z 21 vs.  5, n Z 34). Statistical significance
levels of intergroup differences are given in the text.
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vitality, emotional functioning, social, role, eating distur-
bances and digestive symptoms domains (Table 2). There
were no significant correlations between the PSQI scores
and those on the physical functioning, weight and respira-
tory symptoms domains of the CFQ18 þ R.Discussion
In the present study, we observed that compared with age-
and sex-matched healthy controls daytime sleepiness and
poor sleep quality were more frequently encountered inTable 2 Uni-and multivariate correlations between scores on t
CFQ18 þ R domain Correlation
coefficients
Unadjusted
p-value
Physical functioning 0.205 0.137
Vitality 0.429 0.001
Emotional functioning 0.598 <0.001
Social 0.293 0.032
Role 0.259 0.061
Body image 0.180 0.194
Eating disturbances 0.310 0.023
Treatment burden 0.194 0.164
Health perceptions 0.176 0.202
Weight 0.092 0.507
Respiratory symptoms 0.183 0.185
Digestive symptoms 0.369 0.006
a Adjusted for age, gender, BMI, FEV1/VC and pseudomonas status.clinically stable adult CF out-patients. Every fifth of these
patients felt sleepy and every third reported reduced
sleep quality. These data are in line with earlier reports
investigating daytime well-being and sleep quality in
CF.10e14
Evaluation of disease-specific HRQoL by the CFQ18 þ R
showed that our patients had moderate impairments in the
domains of this questionnaire with more pronounced
changes in those patients who were sleepy or had poor
sleep quality.
Further statistical analysis revealed that daytime
sleepiness as evaluated by the ESS was not significantly
related to HRQoL in the CF patients investigated. However,he PSQI and the different domains of the CFQ18 þ R.
Standardized
coefficients
Adjusted
p-valuea
95% CI
0.255 0.074 5.386/0.262
0.463 0.001 4.661/1.281
0.655 <0.001 5.711/2.701
0.336 0.022 3.871/0.309
0.336 0.020 0.080/0.007
0.212 0.086 4.467/0.035
0.309 0.034 0.076/0.003
0.201 0.145 3.948/0.599
0.225 0.099 4.234/0.380
0.160 0.279 0.072/0.022
0.256 0.069 3.795/0.149
0.361 0.008 0.071/0.011
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marker of daytime sleepiness as has for instance been
shown in patients with obstructive sleep apnea.20 Further-
more, the different items of the ESS are linked to specific
situations which may not have been encountered by the
individual respondents.
A novel finding was that poor sleep quality was signifi-
cantly related to certain aspects of reduced disease-
specific HRQoL in CF even after adjustment for confound-
ing variables such as age, gender, BMI, lung function and
pseudomonas status. Higher scores on the PSQI correlated
with lower scores on those domains of the CFQ18 þ R
representing mental health (i.e. vitality, emotional func-
tioning, social and role). Thus, it may be speculated that
psychological factors such as anxiety and depression lead to
reduced sleep quality in CF. In addition, it may be possible
that pancreatic insufficiency or other gastrointestinal
disease causing abdominal pain worsens sleep quality in CF.
This is suggested by the observation that higher PSQI scores
also correlated with lower CFQ18 þ R scores for eating
disturbances and digestive symptoms.
Somewhat unexpected, the PSQI scores did not signifi-
cantly correlate with those of the physical functioning,
weight and respiratory symptoms domains of the
CFQ18 þ R. However, this may be explained by the fact that
our patients had on an average almost normal body weight
and moderately reduced pulmonary function. Furthermore,
it may be related to the design of the study excluding those
CF patients with ongoing or recent pulmonary
exacerbations.
It should be acknowledged that, based on our data, it is
not possible to establish causeeeffect relationships
between poor sleep quality and reduced HRQoL in CF. In
order to clarify this issue, future studies could for example
perform randomized, controlled therapeutic interventions
to improve sleep quality and then re-evaluate HRQoL in
these patients. Based on the results of our study, we
propose that psychological support may be of special value
to improve sleep quality in CF. Nutritional counseling aimed
at reducing abdominal discomfort and pain may be another
option.
Our study has some possible limitations. First, we did
not perform polysomnographic studies and therefore
could not gain insight into the patients’ sleep architec-
ture, i.e. objective sleep quality. For the same reason, it
is also not possible to judge if poor sleep quality was due
to breathing anomalies while asleep. The latter point is of
considerable interest as a recent study reported that CF
patients with nocturnal oxygen desaturations have
impaired quality of life.21 Second, we did not carry out
multiple sleep latency tests which would have enabled us
to rate the degree of daytime sleepiness of the patients.
Third, it should be realized that the ESS and PSQI have not
yet been validated in CF. Nevertheless, we employed the
cut-off values which have been reported in other patient
populations to separate individuals with vs. without
daytime sleepiness/poor sleep quality to describe our
findings. Finally, QoL was not evaluated in the control
group. However, it must be considered that the ques-
tionnaire used in the present study, i.e. the CFQ18 þ R, is
specifically designed for use in people with CF. Thus, to
compare QoL in CF and controls, it would have beennecessary that both groups responded to a generic QoL
questionnaire such as the SF-36.
We conclude that self-reported daytime sleepiness and
impaired sleep quality are more common in clinically stable
adult CF out-patients than in age- and sex-matched healthy
controls. In addition, poor sleep quality is related to
reduced disease-specific HRQoL. Although these observa-
tions clearly need further study, they do suggest that more
attention should be paid to sleep-related symptoms in
individuals with CF.Conflict of interest
None of the authors has any conflict of interest to disclose.
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